<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345761</url>
  </required_header>
  <id_info>
    <org_study_id>JO19380</org_study_id>
    <nct_id>NCT00345761</nct_id>
  </id_info>
  <brief_title>Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer</brief_title>
  <official_title>Phase I/II Study of R340 (Capecitabine), L-OHP (Oxaliplatin) and R435 (Bevacizumab) in Advanced and/or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yakult Honsha Co., LTD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety and pharmacokinetics of capecitabine (2000
      mg/m2/day by mouth [po], day 1 pm-day 15 am every 3 weeks [q3w]), oxaliplatin (130 mg/m2
      intravenously [iv], day 1 q3w) and bevacizumab (7.5 mg/kg iv, day 1 q3w) in patients with
      advanced and/or metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the efficacy, safety and pharmacokinetics of Capecitabine (2000
      mg/m2/day po, day 1 pm-day 15 am q3w), Oxaliplatin (130 mg/m2 iv, day 1 q3w) and Bevacizumab
      (7.5 mg/kg iv, day 1 q3w) in patients with advanced and/or metastatic colorectal cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate: Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>event driven</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety (Common Terminology Criteria for Adverse Events [CTCAE] version 3.0)</measure>
    <time_frame>throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>event driven</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>event driven</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to response</measure>
    <time_frame>event driven</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>event driven</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentrations of R340 and its metabolites</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentrations of platinum</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentrations of bevacizumab</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentrations of vascular endothelial growth factor (VEGF)</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentrations of anti-bevacizumab antibody</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Step 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Step 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Step 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)</description>
    <arm_group_label>Step 2</arm_group_label>
    <arm_group_label>Step 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)</description>
    <arm_group_label>Step 1</arm_group_label>
    <arm_group_label>Step 2</arm_group_label>
    <arm_group_label>Step 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)</description>
    <arm_group_label>Step 1</arm_group_label>
    <arm_group_label>Step 2</arm_group_label>
    <arm_group_label>Step 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients 20-74 years of age

          -  Histologically confirmed colorectal cancer

          -  Metastatic and/or locally advanced colorectal cancer not previously treated with
             chemotherapy for metastatic disease

          -  At least one measurable lesion according to RECIST

        Exclusion Criteria:

          -  Evidence of clinically detectable ascites at study treatment start

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to study treatment start, or anticipation of the need for major surgical
             procedure during the course of the study; fine needle aspiration within 7 days prior
             to study treatment start.

          -  Evidence of bleeding diathesis or coagulopathy

          -  Serious, non-healing wound, ulcer, or bone fracture

          -  Chronic, daily aspirin (&gt; 325 mg/day), anticoagulants, or other medications known to
             predispose to gastrointestinal ulceration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuji Hayashi</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Development Department 3, Group 6</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hokkaido Region</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto Region</name>
      <address>
        <city>Kanto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki Region</name>
      <address>
        <city>Kinki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai Region</name>
      <address>
        <city>Tokai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2006</study_first_submitted>
  <study_first_submitted_qc>June 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2006</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chugai Pharmaceutical CO.,LTD</name_title>
    <organization>Chugai Pharmaceutical CO.,LTD</organization>
  </responsible_party>
  <keyword>Advanced and/or metastatic colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

